These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25463990)

  • 21. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K; Komatsuda A; Yanai Y; Niwa N; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Oya M
    J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
    Patel R; Lepor H; Thiel RP; Taneja SS
    Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?
    Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
    Radiat Oncol; 2016 Jul; 11():102. PubMed ID: 27475986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
    J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
    Ploussard G; Staerman F; Pierrevelcin J; Saad R; Beauval JB; Roupret M; Audenet F; Peyromaure M; Delongchamps NB; Vincendeau S; Fardoun T; Rigaud J; Villers A; Bastide C; Soulie M; Salomon L;
    J Urol; 2013 Nov; 190(5):1750-6. PubMed ID: 23643600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?
    Simon RM; Howard LE; Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Vidal AC
    BJU Int; 2016 Jun; 117(6):897-903. PubMed ID: 26010251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins.
    Simon MA; Kim S; Soloway MS
    J Urol; 2006 Jan; 175(1):140-4; discussion 144-5. PubMed ID: 16406892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
    Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
    J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.